VTI Recovers Liver Assist Technology, Manufacturing Plant From VitaGen
This article was originally published in The Gray Sheet
Executive Summary
Vital Therapies, Inc. plans to commence Phase III clinical trials in 2004 for its ELAD extracorporeal liver assist device for bridge-to-liver transplant or potential liver recovery
You may also be interested in...
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Startups Persevere Toward Gaining Artificial Liver Approval
The potential market opportunity for an artificial liver keeps players in the game, even though many companies have tried and failed in the past
Financings In Brief
Vital Therapies funds artificial liver development: Start-up raises $28.1 million in a "Series C" private placement to support further development of its ELAD extracorporeal liver assist device, the firm announces Sept. 12. The San Diego company is conducting a pivotal trial of the human cell-based artificial liver in China to support a planned near-term marketing application in that country, "and to provide more safety data for U.S. registration," according to the company. The firm anticipates Chinese approval this year and a U.S. market go-ahead by the end of the decade. ELAD, which is regulated as a biologic by FDA with input from the agency's device center, is intended as a bridge-to-transplant or for potential liver recovery for patients with severe liver failure. Vital Therapies acquired the bedside-use technology in 2003 from VitaGen (1"The Gray Sheet" Oct. 6, 2003, p. 26). The recent financing round was led by Versant Ventures